PerkinElmer is pleased to announce the newest Addition to PerkinElmer’s Molecular-based Product Portfolio and aCGH Product Family. The Constitutional Chip 4.0 for aCGH studies demonstrates continued synergies, resulting from the spectral genomics, Inc. asset acquisition Features and benefits of the Constitutional Chip 4.0 include; more well-characterized clinically significant chromosomal regions — 4.0 is composed of >5000 BAC clones spaced at a mathematical average of 610kb intervals throughout the genome, covering 25 percent of the human genome; enhanced detection of supernumerary marker chromosomes as a result of a product design featuring more than 100 BAC clones in close proximity to the centromere; high resolution detection of chromosomal gains and losses across the entire X chromosome due to 600 BAC clones creating a near tiling coverage with an average gap size of only 100kb; and comprehensive back bone coverage for improved overall coverage throughout the genome. The Constitutional Chip 4.0 is designed to be used as part of PerkinElmer’s complete aCGH solution, including aCGH reagents, ScanArray® scanners and image processing software, and SpectralWare® aCGH analysis software. PerkinElmer, (NYSE: PKI, www.perkinelemer.com), a leading provider of drug discovery, genetic screening, environmental and chemical analysis tools and instrumentation. § High-Quality BAC Array is Newest Addition to PerkinElmer’s Molecular-based Product Portfolio and aCGH Product Family § Latest Innovation Demonstrates Continued Synergies Resulting From the Spectral Genomics, Inc. Asset Acquisition WASHINGTON – PerkinElmer, Inc., a global leader in Health Sciences and Photonics, today announced the Constitutional Chip® 4.0 microarray for array-based comparative genomic hybridization (aCGH) at the American Association for Clinical Chemistry (AACC) 2008 Annual Meeting and Clinical Lab Expo in Washington, DC. This newest addition to PerkinElmer’s genetic screening molecular-based product portfolio is a high-quality bacterial artificial chromosome (BAC) array intended for identification of chromosomal gain or loss of DNA and identification of the region in which gain or loss has occurred. The Constitutional Chip 4.0 combines leading technology from PerkinElmer’s Constitutional Chip 3.0 and the Spectral Chip™ 2600, obtained through the Company’s acquisition of the assets of Spectral Genomics, Inc., along with additional features and functionality to provide cytogenetic laboratories with enhanced detection capabilities. “Cytogenetic research can benefit tremendously if researchers are able to combine a targeted array approach with whole genome coverage to maximize detection rates,” said Ann-Christine Sundell, president, genetic screening, PerkinElmer. “Our latest innovation, the Constitutional Chip 4.0, enables researchers to do just that: assure reliable research of gains and losses related to significant well-characterized chromosomal regions as well as identify novel copy number changes and define break points. We are pleased to be able to continue to provide our customers worldwide with the total technology solutions they require to improve results and change lives outside the laboratory walls.” Current cytogenetic research is focused on exploring the genetic cause(s) associated with dysmorphic features, unexplained mental retardation or developmental delay, multiple congenital anomalies or any suspicion of genomic imbalance. aCGH technology has recently become an important component of this type research due to its ability to detect genomic copy number changes at a higher resolution level than traditional karyotyping methods, such as FISH or g-banding. PerkinElmer’s aCGH technology provides the speed, throughput and resolution required for today’s cytogenetic laboratories, allowing researchers to survey the entire human genome with high resolution and specificity. Features and benefits of the Constitutional Chip 4.0 include: More well-characterized clinically significant chromosomal regions — 4.0 is composed of >5000 BAC clones spaced at a mathematical average of 610kb intervals throughout the genome, covering 25 percent of the human genome; >90 well characterized chromosomal regions covered by >1200 BAC clones providing an average resolution of 420kb with an average of 15 BAC clones per region; Improved subtelomere coverage—10Mb of each subtelomere is covered with an average resolution of 450 kb and altogether there are more than 900 subtelomere BAC clones on the subtelomeric regions; Enhanced detection of supernumerary marker chromosomes as a result of a product design featuring more than 100 BAC clones in close proximity to the centromere; High resolution detection of chromosomal gains and losses across the entire X chromosome due to 600 BAC clones creating a near tiling coverage with an average gap size of only 100kb; and Comprehensive back bone coverage for improved overall coverage throughout the genome. The Constitutional Chip 4.0 is designed to be used as part of PerkinElmer’s complete aCGH solution, including aCGH reagents, ScanArray® scanners and image processing software, and SpectralWare® aCGH analysis software. The Constitutional Chip 4.0 is the latest addition to PerkinElmer’s genetic screening portfolio, which provides innovative products, services and complete solutions to advance preventive medicine from pre-conception through child health. PerkinElmer is the established global leader in neonatal screening and is committed to growing its offerings in prenatal screening and maternal health worldwide. The Company provides customers with the most comprehensive array of newborn screening solutions available, including the world’s first and only tandem mass spectrometry kit cleared by the FDA, and PerkinElmer Genetics, a full-service newborn screening laboratory. The Company provides families the option of preserving their baby’s umbilical cord blood at the time of birth for possible future medical use in treating more than 70 diseases, many cancers and immunodeficiencies through its ViaCord business. PerkinElmer also provides first-trimester prenatal risk assessment testing under the brand name Ultra-Screen®, through its NTD Laboratories subsidiary. PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.8 billion in 2007, has 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.